Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 8Sarcopenia 2Prostatic Neoplasms 2Obesity 2Melanoma 2Malnutrition 2Colorectal Neoplasms 2Breast Carcinoma In Situ 2Wound Infection 1Weight Loss 1Surgical Wound Infection 1Skin Neoplasms 1Psoriasis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Polycystic Ovary Syndrome 1Phagocyte Bactericidal Dysfunction 1Pain 1Paget's Disease, Mammary 1Osteoarthritis 1Olfaction Disorders 1Neoplasms 1Neoplasm, Residual 1Mandibular Neoplasms 1Lymphoma, Follicular 1Lipid Metabolism Disorders 1Huntington Disease 1Fatigue 1Diabetes Mellitus 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × Docosahexaenoic Acids × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡